US FDA Generic Approvals Peak In April, But Annual Pace Trends Down
Executive Summary
The April total is the highest monthly total in seven months, but only a few are first generics. Approval volume might continue rising if FDA does not find too many applications requiring in-person inspections, which were largely postponed as part of coronavirus containment measures, Robert Pollock, senior advisor and outside director to the board at Lachman Consultants, said.
You may also be interested in...
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
ANDA Submissions Drop To Start FY 2021, Perhaps Forced Down By COVID-19
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
Woodcock's Prophesy Comes True: US FDA ANDA Approvals Decline From Record Levels
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.